Shire's lifitegrast will help boost market for dry eye treatment to $4.6 billion by 2024 - GlobalData

5 November 2015

The global treatment market for dry eye syndrome will more than double in value to $4.6 billion by 2024 from about $2.2 billion in 2014, a 7.9% rise, according to research and consulting firm GlobalData.

According to a report by the company the rise, which will occur across the nine major markets of the USA, France, Germany, Italy, Spain, the UK, Japan, China, and India, will be driven primarily by the introduction of novel drugs, most notably Ireland-headquartered drugmaker Shire’s (LSE: SHP) lifitegrast, a drug with anti-inflammatory benefits.

Catherine Daly, senior analyst at GlobalData says, the paucity of dry eye syndrome treatments in the USA and European markets will allow Shire to secure strong uptake and a sizable market share for lifitegrast.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK